当前位置：
X-MOL 学术
›
Lancet Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
The Lancet Oncology ( IF 41.6 ) Pub Date : 2024-10-28 , DOI: 10.1016/s1470-2045(24)00387-5 Mafalda Oliveira MD, Denys Pominchuk PhD, Prof Zbigniew Nowecki MD, Erika Hamilton MD, Yaroslav Kulyaba MD, Timur Andabekov PhD, Prof Yevhen Hotko MD, Tamar Melkadze MD, Prof Gia Nemsadze MD, Prof Patrick Neven MD, Vladimir Vladimirov MD, Claudio Zamagni MD, Hannelore Denys MD, Frédéric Forget MD, Zsolt Horvath MD, Alfiya Nesterova MD, Maxine Ajimi PhD, Bistra Kirova MBChB, Teresa Klinowska PhD, Justin P O Lindemann MBChB, Delphine Lissa PharmD, Alastair Mathewson PhD, Christopher J Morrow PhD, Zuzana Traugottova MD, Ruaan van Zyl PhD, Ekaterine Arkania MD
The Lancet Oncology ( IF 41.6 ) Pub Date : 2024-10-28 , DOI: 10.1016/s1470-2045(24)00387-5 Mafalda Oliveira MD, Denys Pominchuk PhD, Prof Zbigniew Nowecki MD, Erika Hamilton MD, Yaroslav Kulyaba MD, Timur Andabekov PhD, Prof Yevhen Hotko MD, Tamar Melkadze MD, Prof Gia Nemsadze MD, Prof Patrick Neven MD, Vladimir Vladimirov MD, Claudio Zamagni MD, Hannelore Denys MD, Frédéric Forget MD, Zsolt Horvath MD, Alfiya Nesterova MD, Maxine Ajimi PhD, Bistra Kirova MBChB, Teresa Klinowska PhD, Justin P O Lindemann MBChB, Delphine Lissa PharmD, Alastair Mathewson PhD, Christopher J Morrow PhD, Zuzana Traugottova MD, Ruaan van Zyl PhD, Ekaterine Arkania MD
Resistance to endocrine therapies in hormone receptor-positive breast cancer is challenging. We aimed to assess the next-generation oral selective oestrogen receptor degrader (SERD) and complete oestrogen receptor antagonist, camizestrant, versus the first-approved SERD, fulvestrant, in post-menopausal women with oestrogen receptor-positive, HER2-negative, advanced breast cancer.
中文翻译：
Camizestrant，一种下一代口服 SERD，与氟维司群在雌激素受体阳性、HER2 阴性晚期乳腺癌 （SERENA-2） 绝经后妇女中的疗效：一项多剂量、开放标签、随机、2 期试验
激素受体阳性乳腺癌对内分泌治疗的耐药性具有挑战性。我们旨在评估下一代口服选择性雌激素受体降解剂 （SERD） 和完全雌激素受体拮抗剂 camizestrant 与首次批准的 SERD 氟维司群在雌激素受体阳性、HER2 阴性晚期乳腺癌绝经后妇女中的疗效。
更新日期：2024-10-28
中文翻译：
Camizestrant，一种下一代口服 SERD，与氟维司群在雌激素受体阳性、HER2 阴性晚期乳腺癌 （SERENA-2） 绝经后妇女中的疗效：一项多剂量、开放标签、随机、2 期试验
激素受体阳性乳腺癌对内分泌治疗的耐药性具有挑战性。我们旨在评估下一代口服选择性雌激素受体降解剂 （SERD） 和完全雌激素受体拮抗剂 camizestrant 与首次批准的 SERD 氟维司群在雌激素受体阳性、HER2 阴性晚期乳腺癌绝经后妇女中的疗效。
京公网安备 11010802027423号